• Meeting will be at Swissotel in Beijing, China, on September 29 at 10:00 a.m. local time in order to accommodate more shareholders; the new record date is August 30, 2017
• SeeThruEquity projects that Moxian revenues will reach $24.1 million by FY2018
• Moxian is targeting a Chinese mobile market of 1.3 billion people, the world’s largest

Moxian, Inc. (NASDAQ: MOXC) has changed both its venue and record date for its 2017 general meeting of stockholders. The new record date is August 30, 2017, and the location of the meeting has been moved to the Swissotel in Beijing, China, in the Hong Kong Macau Center.

The meeting’s time and date remain unchanged. It will held on September 29 at 10 a.m. local time, which is 10 p.m. ET on September 28.

Moxian is headquartered in Shenzhen, China, with offices in Beijing, Malaysia and Hong Kong. It is an online-to-offline (O2O) integrated platform operator. The company is converting its unpaid platforms to paid. It has the Moxian+ Business mobile app, which generates revenue by connecting consumers to small- and medium-sized market enterprises (SMEs) through social platforms, games and rewards available through earned Mo-Points. Client merchants can then learn more about consumers, completing online sales via their own brick-and-mortar offline stores.

The company generates revenues via subscription and licensing income, selling premium consumer data to merchant clients, advertising, and a percentage of all transactions. Moxian already has 31,600 merchants on Moxian+ Business. By mining data gleaned through analytics, Moxian enables vendor clients to promote and market their products.

To consumers, it offers the Moxian+ User app. It has some 300,000 registered users on this platform, which is also being converted to paid, and offers social events, contests and prizes. The company also has the proprietary Mo-Talk, a voice-chat service on both apps, enabling client merchants and consumers to interact.

SeeThruEquity estimates that the company will generate revenues of $24.1 million by FY2018 (http://dtn.fm/Po0qP). Moxian is targeting a Chinese mobile phone market of 1.3 billion people, the research firm notes, quoting China’s Ministry of Industry and Technology statistics. That market is the largest of its kind in the world.

For more information, visit the company’s website at www.Moxian.com

• ABcann’s low current market cap compared to similar companies offers an obvious opportunity for investors
• ABcann Global is one of Canada’s most dominant growers of medical marijuana and one of the growers to meet Canadian government’s stringent licensing requirements
• Major expansion of ABcann’s production capacity is underway

An interesting opportunity for investors can be found in ABcann Global Corporation (TSX.V: ABCN) (OTCQB: ABCCF), a Canadian grower of medical marijuana. ABcann recently acquired ABcann Medicinals and boasts a recent IPO, appointment of a new medical consultant, and major expansion plans.

ABcann is new to the public market, having launched its initial public offering on May 4. However, the company is one of the most experienced Canadian growers. ABcann is one of Canada’s dominant medical growers, producing organically grown, pesticide-free medicinal-grade marijuana using scalable, proprietary growing technology, which allows the consistent generation of high-quality products.

The company’s low current market cap offers an obvious opportunity for investors, as ABcann compares well with other companies in the industry. For example, Supreme Pharmaceuticals has a market cap of $250 million, and Hydropothecary Corp. is valued at $150 million. Emblem Corp. – with the same size growing facility as ABcann – is valued at $200 million.

ABcann’s expansion plans are ramping up, and its proprietary, advanced growing technology is highly scalable. A new chamber is planned for the company’s current facility in Napanee, Ontario, which currently produces 1,000 kilograms annually.

In addition, land has already been purchased for a new 71,000 square-foot facility which will have a production capacity of 20,000 kilograms each year – 20 times ABcann’s current production. In further plans, a 65-acre property for a planned 1.2 million square-foot growing facility is ready for development.

One of the first companies to obtain a production license under Canadian Marijuana for Medical Purposes Regulation, ABcann acquired a license in March 2014. Only three percent of companies that apply for a license make it through the extensive six-step process, which requires a comprehensive background check and prior investment in a growing facility.

In July, ABcann announced its inclusion in the Horizons Medical Marijuana Life Sciences ETF (TSX: HMMJ). The ETF index selects companies with operations in biopharmaceuticals, medical manufacturing, distribution, and other marijuana industry services.

In June, the company announced the appointment of Dr. Michael Shannon as chief medical consultant. Shannon brings a long history of health care experience in the private and public sectors and joins an all-star management and advisory team which includes Dr. Raphael Mechoulam, a professor of medicinal chemistry at Hebrew University of Jerusalem who is widely regarded as the “Father of Marijuana Research.”

For more information, visit the company’s website at www.ABcann.ca

• InMed to test INM-750 in vitro, estimates clinical trials for 2018-2020
• ATERA SAS to develop 3D skin models to help pre-clinical tests of INM-750
• INM-750 being developed to treat skin disease epidermolysis bullosa, with a successful therapy having potential global market of $1 billion

InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a biopharmaceutical company focused on identifying and commercializing prescription drugs using non-THC cannabinoids, recently reached a research and development agreement with tissue engineering company ATERA SAS of France (http://dtn.fm/Yv6Bd). The fundamental benefits of this agreement for InMed, as it eyes a clinical trial program, are a proprietary assessment tool, a biosynthesis manufacturing process, and drug development programs.

Vancouver-based InMed’s lead compound is INM-750, a proprietary topical cannabinoid product candidate aimed at treating skin disease epidermolysis bullosa (EB). EB is a skin disease which retards wound healing and can cause pain, itching, and inflammation. INM-750 may reverse the disease, for which there are currently no approved therapies. In its corporate presentation, InMed said that it sees a potential global market of $1 billion for INM-750, if approved.

ATERA SAS, as part of the agreement, will develop 3D human skin models that will assist InMed in assessing INM-750’s effectiveness in treating EB in vitro ahead of upcoming clinical trials estimated by InMed to take place in 2018, 2019 and 2020. ATERA SAS will produce 3D skin models in a controlled environment, creating a unique tool for drug development screening. ATERA SAS is expected to develop the 3D models from EB patient biopsies in order to help InMed assess INM-750.

ATERA SAS is a tissue engineering company tasked in this agreement with developing advanced human tissue models to assist InMed in analyzing pre-trial tests. The French company will also investigate INM-750 at the ultra-structural cellular and molecular levels. It will create 3D in vitro reconstructed human full thickness skin models of both normal and EB-derived skin cells.

At InMed, Dr. Ado Muhammed, MD, DPM and MFPM, is the chief medical officer. He previously served as associate medical director at GW Pharmaceuticals, where he was key in leading the company in the development and FDA approval of one of the first cannabis drugs. InMed is the only cannabis biotech company led by a former GW Pharmaceuticals executive.

For more information, visit the company’s website at www.InMedPharma.com

Let us hear your thoughts: InMed Pharmaceuticals, Inc. Message Board

In an interview with Stock Day, CEO Chris Bunka of Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) discussed the company’s recent achievements and its plans for the near future. Revenues are climbing, exceeding, so far in 2017, the total for all of 2016, and the potential for further increases is imminent. The company is in negotiation with at least four large pharmaceutical companies to license its technology. The smallest of these could increase revenues by $1 million; the largest could increase revenues by much, much more, according to Bunka. Getting any of these deals signed will boost the bottom line almost as much as they would raise revenues. Lexaria will be employing a lucrative licensing model that is likely to yield 90-100% of revenues as profit. The company expects to have its first major agreement wrapped up by the end of the year.

Apart from attracting the attention of big pharma, Lexaria has been working with the National Research Council (NRC) of Canada, an agency of the Canadian federal government, to explore the effects of its technology. The company has developed technology that allows non-psychoactive cannabinoids, vitamins, non-steroid anti-inflammatory drugs (NSAIDs) and nicotine to be absorbed at much higher rates. Lexaria’s superior delivery system offers the promise of potentially reducing required doses of these substances, since less of them goes to waste. The technology also speeds up delivery. It can deliver payload molecules to the bloodstream in 15-25 minutes, as opposed to 60-90 minutes for current methods, and is already in use in a number of consumer products.

Lexaria recently raised $4 million in capital. The company intends to spend part of the proceeds in setting up an R&D program for nicotine. The initiative comes at an opportune time. In August, the FDA announced “a new comprehensive plan for tobacco and nicotine regulation that will serve as a multi-year roadmap to better protect kids and significantly reduce tobacco-related disease and death” (http://dtn.fm/hlb4O). The agency plans to stimulate public dialogue on lowering nicotine levels in combustible cigarettes to non-addictive levels. This is good news for Lexaria, which is hoping its technology can provide a delivery method for nicotine that is safer than smoking. As its CEO has remarked, “Regulation is great news for Lexaria.”

The interview can be heard at http://dtn.fm/194Mx

For more information, visit the company’s website at www.LexariaEnergy.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

• Multi-billion industry growing at a compound annual growth rate of 31%
• Unique business plan providing ground-floor investment opportunities
• Existing portfolio with flagship app once ranking as #1 iOS family game in five countries

AppSwarm, Inc. (OTC: SWRM) is a technology development and incubation acceleration company that partners up with developers through joint ventures, royalty agreements, marketing partnerships, and outright purchase agreements. Focusing on the ever-growing mobile applications market, the company provides all the resources needed for engagement, retention, virality and monetization.

The global games market generated approximately $100 billion in revenues in 2016, but large global game companies have made it extremely difficult for smaller developers to achieve success in the marketplace. As a result, many great ideas aren’t monetized. AppSwarm solves this problem by providing the funding and critical business expertise needed to successfully launch and market new applications.

Business applications is another area of focus for the company. Targeting small to medium sized businesses, AppSwarm will be developing and acquiring mobile application tools and platforms that increase productivity and security via data encryption, cloud storage, content management and delivery, digital payments, automation, and customer loyalty marketing solutions. Recent acquisitions made so far represent only a small example of future planned initiatives to develop and market tools for the business community.

Regardless of the target market, AppSwarm can help developers accelerate the success of their app through funding, technology and marketing expertise, as well as a unique eco system that accelerates user acquisition. The company is able to assist at any state of development with completion of concept, market analysis, business and financial management, direct sales and marketing, social game development to ensure correct product application and expedient deployment with cost efficiency.

Ron Brewer, CEO of the company, has accumulated extensive leadership in the technology sector and brings valuable knowledge gained as a Director of Southbridge Advisory Group for nearly 20 years. Ron’s C-level experience includes merger & acquisition and post-acquisition turnaround in both the private and small-cap public sector. John Rabbit, director of finance, is a seasoned business veteran that has worked with Fortune 500 firms and served in CEO, COO and CFO positions for firms ranking from $5 million to $300 million in annual revenues. John was directly involved in numerous acquisitions and served in executive capacities for several multinational subsidiaries.

With a well-suited management team, multiple synergistic revenue streams, and diversified growth strategy, AppSwarm is well positioned in a steadily growing industry with countless opportunities for capitalization.

For more information, visit the company’s website at www.App-Swarm.com

Let us hear your thoughts: AppSwarm, Inc. Message Board

• Leading-edge provider of prepaid card programs and processing services
• Portfolio includes millions of prepaid debit cards
• Company serves some of the largest pharmaceutical manufacturers in the world

Operating at the cutting edge of innovation, 3PEA International, Inc. (OTCQB: TPNL) is a vertically integrated prepaid card programs and processing services provider, offering solutions for corporate, consumer and government applications. The company is revolutionizing the payments market, catering to a variety of users and industries with innovative solutions and options designed to streamline operations, reduce costs, boost revenue, accelerate product adoption and bolster loyalty.

A trusted and experienced payment processor and provider of prepaid debit card payment solutions, 3PEA International boasts millions of prepaid debit cards within its portfolio. Through its PaySign® brand, the company designs and develops payment solutions, prepaid card programs and customized payment services.

3PEA provides and manages programs for some of the largest pharmaceutical manufacturers in the world, offering co-pay assistance products that are designed to maximize acquisition, retention and adherence of patients. The company also offers corporate incentive prepaid cards, which are transforming the way corporations reward, motivate and engage their existing customers, potential customers, employees and agents.

The customizable prepaid solutions offered by 3PEA enable substantial cost savings and also enhance brand recognition and customer loyalty. The company’s customers include health care companies, major pharmaceutical companies and source plasma providers, large multinationals, prominent universities and social media companies.

Marketed under the proprietary PaySign brand, 3PEA’s solutions are designed to attain measurable results through motivating actions and behaviors. Whether clients are seeking a way to reward consumers, agents, employees or channel partners, 3PEA’s PaySign products provide a solution to meet their specific needs.

For more information, visit the company’s website at www.3PEA.com

• Proposed legislation would remove cannabis from the list of Schedule I controlled substances.
• If successful, it would pave the way for the Canadian company to enter the U.S. market.
• Unique combination of algae and cannabis oils targeting cancer and mental health disease, making Algae Dynamics a lucrative opportunity for investors.

A bill looking to decriminalize marijuana all over the country has recently been introduced in the U.S. Senate, giving fresh hope to legal cannabis businesses that they will be able to expand operations and access federal protections and banking solutions. The bill, titled the Marijuana Justice Act, was introduced by New Jersey Democrat Senator Cory Booker, being designed to reverse the tough federal stance on cannabis and hopefully resolve the ongoing conflict between federal and state laws on cannabis. While still classified as a Schedule I drug on par with heroin, cocaine and LSD at the federal level, marijuana is already legal in 29 states and the District of Columbia either for medical or recreational use. If successful, the bill would allow companies such as Algae Dynamics Corp. (OTCQB: ADYNF) to operate freely in the United States in an entirely legal and regulated market.

The Marijuana Justice Act would remove cannabis from the federal list of drugs on the Controlled Substances Act, according to the Investing News Network (http://dtn.fm/6g9D3). The bill would incentivize states that still oppose marijuana legalization to update their legislation and would also allow prisoners serving a sentence on marijuana possession charges to ask for resentencing.

In a statement, Booker explained that his bill is aimed at helping the current “broken” state of U.S. drug laws. Instead of making communities safer, current drug laws waste billions in taxpayer money, diverting resources from fighting violent crimes and tearing families apart, with an unfair impact on low-income communities and communities of color, the statement said.

Supporters of decriminalization expect tough opposition to the bill, with known opponent Attorney General Jeff Sessions currently seeking Congressional support to remove protections on medical marijuana use at state level and to get a targeted look at MMJ users.

Analysts think the bill is unlikely to pass at this time, but are optimistic that it will stimulate a conversation in Congress on the topic. Cannabis financial analyst Alan Brochstein voiced hope that Senator Booker’s bill would at least get lawmakers to focus on some of the issues the industry is facing – most notably the absence of federal banking support and the lack of sufficient research. But if the bill is successful, it would catapult an already booming industry and open capital markets by removing a series of impediments currently blocking the market, such as access to banking, interstate transport and research, Brochstein said.

The federal decriminalization of marijuana would allow Algae Dynamics Corp., based in Canada but publicly traded in the U.S., to enter the American market with its unique product line that combines the health benefits of algae, hemp and cannabis oils. The U.S. cannabinoid market is expected to reach $2 billion in sales by 2020 and an impressive $50 billion by 2029, according to Statista figures (http://dtn.fm/Bdu6c). This would provide Algae Dynamics with ample opportunities to successfully market its innovative blend of algae and cannabis oils, making the company an ideal target for investors in the fast-growing cannabinoid and cannabis industries. For the time being, the company operates only in Canada, where the marijuana oil extraction market is projected to grow exponentially, from C$1 million in 2015 to approximately C$1.7 billion in 2020, with full cannabis legalization expected in the country in 2018.

Algae Dynamics Corp.’s health and pharmaceutical products primarily target cancer and mental ailments, and the company has already partnered with two Canadian universities to research the use of cannabis oil in these fields. The company has signed a three-year, C$600,000 partnership with the university of Waterloo to research the effects of cannabis oils on pancreatic, colorectal, prostate and breast cancer, and a four-year, C$1 million research agreement with the University of Western Ontario to assess the use of cannabis derivatives for mental health diseases including anxiety, PTSD, depression and schizophrenia.

For more information about the company and its innovative products, visit www.AlgaeDynamics.com

Let us hear your thoughts: Algae Dynamics Corp. Message Board

Global Payout, Inc. (OTC: GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout’s fully configurable “banking-in-a-box” web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today’s banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout’s management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and “high-risk” market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and “high-risk” enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions.

For more information, visit the company’s website at www.GlobalPayout.com

Let us hear your thoughts: Global Payout, Inc. Message Board

• Incubator for developers of mobile apps
• Digital game industry continues to grow
• Mobile app development across Apple, RIM, Google and Microsoft Platforms

If you think that movies are big business, you’re right. Then what would you say about the digital game industry, which by most accounts is twice or three times as large? Out of a global population of some 7.5 billion, about 2.2 billion (29%) play ‘video’ games. That’s good, since, according to one academic report, ‘playing video games can boost brain power’. So playing digital games is smart as well as fun, which is why AppSwarm, Inc. (OTC: SWRM) is planning to increase the choice that gamers have. The innovative company is an incubator for the development of mobile apps, which include digital games. With a fast growing portfolio, one of its games may soon be playing at a home near you.

Even though global box office revenues are expected to rise from $38 billion in 2016 to $50 billion by 2020, according to The Statistics Portal (http://dtn.fm/fD3T3), it will be dwarfed by the global digital game industry, expected to generate about $109 billion in revenues in 2017, increasing from $100 billion in 2016. ‘Digital game revenues will account for $94.4 billion or 87% of the global market’, according to New Zoo (http://dtn.fm/f7GoS). Mobile is expected to be the most lucrative segment, with smartphone and tablet gaming growing 19 percent year on year to $46.1 billion, claiming 42 percent of the market. By 2020, mobile gaming may represent more than half of the total games market.

To capitalize on these exciting trends, AppSwarm was established in 2012 as an incubator for digital app developers. Since then, the company has been engaged in acquiring a range of apps for all forms of devices. AppSwarm offers complete, end-to-end services for mobile application development across all major platforms including Apple iPhone, RIM’s BlackBerry, Google’s Android, and Microsoft’s Windows Mobile. The company has agreements in place with all of the major application stores and is able to assist with application development and act as a strategic partner to facilitate increased visibility, thus allowing most small firms, young entrepreneurs and application developers the resources they otherwise would not have to market their applications effectively.

Games are one segment of the app market that AppSwarm is intensely involved with. Most people play digital games to have fun and relax, but details, reported by Science Daily (http://dtn.fm/Z22Bk), of a study conducted by a team at Queen Mary College, University of London show that video games may be less of the idle pursuit that they are often blamed to be. The researchers found that ‘certain types of video games can help to train the brain to become more agile and improve strategic thinking.’ Playing some games increases ‘cognitive flexibility’, our ability to adapt and switch between tasks and to think about multiple ideas at a given time to solve problems. Cognitive flexibility, it seems, enhances creative problem solving and our ability to ‘think outside the box’.

AppSwarm’s current game portfolio includes Turtles, Huh?, which is ranked as the #1 iOS family games app in five countries, ranked in the top five iOS family games app in 22 countries and ranked in the top 10 iOS family games app in 44 countries. Another game, Avenging Soldiers, is a battle game made with stunning quality visuals, precise controls and advanced physics. Still another, Dead Uncleansed, is an exciting “Tower Defense” game set in a near future world where an evil dictator has manufactured and released a virus. The virus is turning the “infected” into evil zombies that are hell-bent on destruction and killing everything in their path, just the sort of game to play before turning in for the night. And then there is Soccers, a soccer game that you can actually play soccer in. With the 21st FIFA World Cup scheduled for Russia next year, AppSwarm already has skin in the game.

For more information, visit the company’s website at www.App-Swarm.com

• Unclear whether amendment will survive in final appropriations bill, but Congressional vote sends message to Attorney General Jeff Sessions
• CIIX is expanding in global market with online cannabidiol store in Shanghai, China, and brick-and-mortar unit to open in San Gabriel, California
• Consilium Global Research estimates that CIIX will outperform cannabis market to achieve revenues of $14.8 million by FY 2020

ChineseInvestors.com, Inc. (OTCQB: CIIX) and other cannabis companies were overjoyed by the July 27 affirmative voice vote by the Senate Appropriations Committee to approve an amendment to a “2018 Commerce, Justice and Science Bill” that bars the federal government from using federal funds to investigate medical marijuana cases within states that have legalized medical marijuana. It is unclear whether the Rohrabacher-Blumenauer amendment will be part of the final appropriations bill.

However, the Senate sent Attorney General Jeff Sessions a clear message in passing this amendment, defying his letter to Congress urging that the amendment not be passed. A total of 29 states and the District of Columbia have made medical marijuana legal, according to ProCon.org (http://dtn.fm/99mOe). In addition, eight states and DC have made recreational use of marijuana legal. To CIIX and other legal cannabis companies, that vote was seen as an important victory enabling them to “solidify their footholds in the marketplace,” according to one published research article (http://dtn.fm/Z7bzM).

CIIX has a goal of becoming the primary Chinese medical cannabis publicly traded company. To that end, the firm has been aggressive in focusing on research and development as well as distribution of cannabidiol-based (CBD) products globally to the Chinese-speaking population.

In China, sales of CBD is legal, while marijuana is not. CIIX has an online store in the free trade zone of Shanghai selling CBD-based products. It has also established a wholly owned subsidiary, CBD Biotechnology Co. Ltd., which plans to market the CBD Magic Hemp Series. The company has filed with the China Food and Drug Administration (CFDA) for this line of non-industrial hemp-infused skincare products. The line is anticipated to launch in August/September 2017.

CIIX believes itself to be a first mover in China, a consumer market of two billion consumers. In other moves, it has incorporated CBD Technology in British Columbia, Canada. CBD Technology will distribute, research, and sell hemp-based CBD plus beverages and food products.

In in its home market of San Gabriel, California, CIIX is preparing to open its first brick-and-mortar store to, in part, distribute its new OptHemp health products line. It will be among the first stores to sell the line.

Consilium Global Research projects that CIIX will reach $14.8 million in revenue by FY 2020 and said that the CBD market will grow by a compound annual growth rate (CAGR) of 80% to $2.1 billion by 2020 (http://dtn.fm/L7hGB). The research firm believes that CIIX will outgrow the market with a 100% CAGR in that time period. It also believes that CIIX has an advantage due to the fact it is well ingrained with native Chinese speakers globally.

For more information, visit the company’s website at www.ChineseInvestors.com

Let us hear your thoughts: ChineseInvestors.com, Inc. Message Board